Unlike Elon Musk's brain-computer interface, Synchron's doesn't require open-skull surgery, and it has an OpenAI chatbot baked in.
A polo legend and a businessman joined forces to copy the player’s greatest horse. But with a single clone worth $800,000, some technologies are a breeding ground for betrayal.
An investigational drug developed by Eolo Pharma is showing promise in animal experiments and an early human trial. It could eventually be an alternative or add-on to popular GLP-1 medications.
House Democrats sent letters to the potential buyers of the genetic testing company, asking how they plan to protect customer genetic data under a change of ownership.
Paradromics, a brain-computer interface startup, inserted its brain implant in a person—briefly—in an early test of its technology.
The Enhanced Games, where athletes are allowed to take performance-enhancing drugs, will host its first event in May. One “enhanced” former Olympic swimmer has already broken the 50-meter freestyle record.
Pharmaceutical giant Eli Lilly alleges the companies are selling off-brand versions of its best-selling diabetes and weight-loss drugs, Mounjaro and Zepbound.
A novel drug that produces a temporary coating in the small intestine could be a new strategy for weight loss—and an alternative to surgeries and GLP-1 drugs.
Startup Colossal Biosciences has edited the DNA of a gray wolf to produce what it says is a de-extincted animal. Does that make it a true dire wolf?
In an advance for treating male infertility, researchers transplanted a patient with his own sperm-forming stem cells that were collected from testicular tissue when he was a child.